1. Nanoparticle-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancers
- Author
-
Andrew Park, Hwanhee Nam, Hye Hyun Ahn, Will West, Catherine Stace, Christopher G. Ullman, Yizong Hu, Martin G. Pomper, Il Minn, Christy Ng, Hai-Quan Mao, Christine V.F. Carrington, and Heng Wen Liu
- Subjects
Lung Neoplasms ,medicine.medical_treatment ,Genetic enhancement ,Science ,Gene Expression ,Inflammation ,Cancer immunotherapy ,Mice, SCID ,Gene delivery ,Article ,Injections ,Mice ,medicine ,Animals ,Humans ,Polyethyleneimine ,Lung cancer ,Gene ,Multidisciplinary ,Molecular medicine ,business.industry ,Gene Transfer Techniques ,DNA ,Genetic Therapy ,medicine.disease ,Interleukin-12 ,Disease Models, Animal ,Nanomedicine ,Interleukin 12 ,Cancer research ,Nanoparticles ,Medicine ,medicine.symptom ,business - Abstract
Treatment of cancers in the lung remains a critical challenge in the clinic for which gene therapy could offer valuable options. We describe an effective approach through systemic injection of engineered polymer/DNA nanoparticles that mediate tumor-specific expression of a therapeutic gene, under the control of the cancer-selective progression elevated gene 3 (PEG-3) promoter, to treat tumors in the lungs of diseased mice. A clinically tested, untargeted, polyethylenimine carrier was selected to aid rapid transition to clinical studies, and a CpG-free plasmid backbone and coding sequences were used to reduce inflammation. Intravenous administration of nanoparticles expressing murine single-chain interleukin 12, under the control of PEG-3 promoter, significantly improved the survival of mice in both an orthotopic and a metastatic model of lung cancer with no marked symptoms of systemic toxicity. These outcomes achieved using clinically relevant nanoparticle components raises the promise of translation to human therapy.
- Published
- 2021